- Health economic evaluations to be performed at multiple UK hospitals
- Significant interest in triaging COVID-19 patients using ResAppDx-EU
- Director, Sales and Marketing (Europe) appointed
Brisbane, Australia, 26 March 2020 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to provide an update on its commercialisation activities in Europe, including the United Kingdom (UK).
ResApp has recently obtained UK Health Research Authority (HRA) approval for a multi-site health economic evaluation of ResAppDx-EU when applied to adults in accident and emergency (A&E) departments. Three highly regarded teaching hospitals will participate: University College London Hospitals, The Royal London Hospital and Addenbrooke’s Hospital, Cambridge. The observational stage of the evaluation will establish a baseline for the resource usage and costs associated with current care pathways for respiratory diagnosis in a UK A&E department, and also compare the accuracy of ResAppDx-EU to a clinical diagnosis. A second, interventional stage is also planned in which the study clinicians will use ResAppDx-EU to guide their diagnoses whilst evaluating the cost and time benefits generated.
A similar study, to evaluate ResAppDx-EU in children at five UK hospitals, has received provisional HRA approval.
“Respiratory disease is one of the most common reasons for visits to healthcare professionals in Europe, whether in general practice suites, in emergency departments or via telehealth. These evaluations will provide important health economic outcome data to support the use of ResAppDx-EU in the A&E setting,” said Tony Keating, CEO and Managing Director of ResApp. “We look forward to demonstrating that using ResAppDx-EU to triage patients can reduce costs, reduce time to treatment and improve patient flow, which have in turn been shown to decrease A&E congestion, give patients a better experience and reduce pressure on staff.”
The COVID-19 pandemic has had a major impact on healthcare globally, including the conduct of clinical studies. As healthcare systems have to prioritise the treatment of patients with COVID-19, recruitment in these UK health economic evaluations will be delayed until the demand placed on UK A&E departments from the pandemic has subsided. ResApp has received a significant amount of interest in the use of its smartphone-based diagnostic technology for the triage of COVID-19 patients and is in detailed discussions with a number of healthcare systems, including in the UK, regarding specific COVID-19 implementations and studies using ResAppDx-EU to triage patients with respiratory symptoms and prioritise patient access to over-burdened clinics.
To support ResApp’s sales and marketing activities in Europe, ResApp has recently appointed Mr Jamie Joint as Director, Sales and Marketing (Europe). Jamie has over 20 years of experience in the medical device industry, building successful sales infrastructure and driving growth on a global scale. Jamie spent the last three years as International Sales Director with MolecuLight, whose lead product is a CE Marked handheld point-of-care wound-imaging device. Prior to MolecuLight, the majority of Jamie’s career was spent at Olympus Medical where he held a number of senior sales and marketing roles in the UK, Middle East and Africa. Jamie will be based in the UK and will start with ResApp in early April.
“The European market is an important commercial opportunity for ResApp and I’m pleased that we’ve been able to recruit a professional of Jamie’s calibre to help build our sales and marketing organisation there,” said Tony Keating, CEO and Managing Director of ResApp. “We are seeing significant growth in the adoption of new digital technologies across the region’s healthcare systems. The UK’s National Health Service is pursuing multiple initiatives using digital technology to transform healthcare and last year announced that telehealth would be a standard of care in the UK within five years. In 2019, Germany introduced the Digital Supply Law to expand the use of telehealth. It is clear that the COVID-19 pandemic is accelerating this transition to digital-first healthcare.”
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies have demonstrated accurate diagnosis of lower respiratory tract disease, upper respiratory tract infection, pneumonia, bronchiolitis, croup, asthma exacerbation/reactive airway disease, chronic obstructive pulmonary disease, chronic obstructive pulmonary disease exacerbation and obstructive sleep apnoea. ResApp’s smartphone-based acute respiratory disease diagnostic test, ResAppDx-EU, is CE Marked in the European Union and TGA approved in Australia. Potential customers of ResApp’s products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world. For more information, visit www.resapphealth.com.au
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2021 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257, South Korean Patent No. 1020812410000 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.